Cancer antigen peptides derived from WT1

Details Cancer antigen peptides derived from WT1 Cancer antigen peptides derived from WT1

2005-03-30

2009-11-24

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S277100, C514S015800, C530S328000

Reexamination Certificate

active

07622119

ABSTRACT:
The present invention relates to HLA-A26-binding cancer antigen peptides derived from WT1, polynucleotides encoding such a peptide, CTL-inducers, and cancer vaccines comprising such a peptide or polynucleotide.

REFERENCES:
patent: 7030212 (2006-04-01), Sugiyama et al.
patent: 2003/0082194 (2003-05-01), Gaiger et al.
patent: 2002 525099 (2002-08-01), None
patent: 00 26249 (2000-05-01), None
patent: WO 01/25273 (2001-04-01), None
patent: WO 03/037060 (2003-05-01), None
Zinszner, H. et al., “Nucleotide Sequence of the HLA—A26 Class I Gene: Identification of Specific Residues and Molecular Mapping of Public HLA Class I Epitopes” Human Immunology, vol. 27, pp. 155-166, 1990.
Bellantuono, I. et al., “Two Distinct HLA-A0201-Presented Epitopes of the Wilms Tumor Antigen 1 Can Function as Targets for Leukemia-Reactive CTL” Blood, vol. 100, No. 10, pp. 3835-3837, 2002.
Liquan, G. et al., Selective Elimination of Leukemic CD34+Progenitor Cells by Cytotoxic T Lymphocytes Specific for WT1, Blood, vol. 95, No. 7, pp. 2198-2203, 2000.
“Funakoshi News”, Frontiers in Life Science, No. 2004 Nen 3 Gatsu 1 Nichi, pp. 1-13, (2004). (With English Translation).
Dal Porto, J. et al., “A Soluble Divalent Class I Major Histocompatibility Complex Molecule Inhibits Alloreactive T Cells at Nanomolar Concentrations”, Proc. Natl. Acad. Sci. USA, vol. 90, pp. 6671-6675, 1993.
Call, K.M. et al., “Isolation and Characterization of a Zinc Finger Polypeptide Gene at the Human Chromosome 11 Wilms' Tumor Locus”, Cell Press, vol. 60, pp. 509-520, 1990.
Gessler, M. et al., “Homozygous Deletion in Wilms Tumours of a Zinc-Finger Gene Identified by Chromosome Jumping”, Letters to Nature, vol. 343, pp. 774-778, 1990.
Menke, A. L. et al., “The Wilms' Tumor 1 Gene: Oncogene or Tumor Suppressor Gene?” International Review of Cytology, vol. 181, pp. 151-212, 1998.
Sugiyama, H., “Cancer Immunotherapy Targeting WT1 Protein”, International Journal of Hematology, vol. 76, pp. 127-132, 2002.
Akihiro Tsuboi, et al., “Enhanced Induction of Human WT1-Specific Cytotoxic T Lymphocytes With a 9-Mer WT1 Peptide Modified at HLA-A*2402-Binding Residues”, Cancer Immunology and Immunotherapy, XP 002961732, vol. 51, No. 11-12, Dec. 2002, 6 Pages.
Alexander Gaiger, et al., “Immunity to WT1 in the Animal Model and in Patients With Acute Myeloid Leukemia”, Blood, XP 002965863, vol. 96, No. 4, Aug. 15, 2000, pp. 1480-1489.
Hideki Ohminami, et al., “HLA Class I-Restricted Lysis of Leukemia Cells by a CD8+Cytotoxic T-Lymphocyte Clone Specific for WT1 Peptide”, Blood, XP 002190642, vol. 95, No. 1 Jan. 1, 2000, pp. 286-293.
J. Konya, et al. “Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein”, Journal of General Virology, vol. 78, pp, 2615-2620 (1997).

Affiliated with

Also associated with

Rating

Cancer antigen peptides derived from WT1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer antigen peptides derived from WT1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer antigen peptides derived from WT1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4132570